---
title: "Stifel Nicolaus Remains a Buy on Insmed (INSM)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285872289.md"
description: "Stifel Nicolaus analyst Stephen Willey has maintained a Buy rating on Insmed (INSM) with a price target of $200.00, while the stock closed at $101.35. Willey, who focuses on the Healthcare sector, has an average return of 9.7% and a success rate of 44.65%. Insmed has a Strong Buy consensus with a price target of $207.79, indicating a potential upside of 105.02%. Barclays also supports a Buy rating with a target of $237.00."
datetime: "2026-05-11T02:45:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285872289.md)
  - [en](https://longbridge.com/en/news/285872289.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285872289.md)
---

# Stifel Nicolaus Remains a Buy on Insmed (INSM)

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Insmed on May 8 and set a price target of $200.00. The company’s shares closed last Friday at $101.35.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Willey covers the Healthcare sector, focusing on stocks such as Disc Medicine, Incyte, and Insmed. According to TipRanks, Willey has an average return of 9.7% and a 44.65% success rate on recommended stocks.

Insmed has an analyst consensus of Strong Buy, with a price target consensus of $207.79, representing a 105.02% upside. In a report released on May 8, Barclays also maintained a Buy rating on the stock with a $237.00 price target.

### Related Stocks

- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PTH.US](https://longbridge.com/en/quote/PTH.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [IRON.US](https://longbridge.com/en/quote/IRON.US.md)
- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus](https://longbridge.com/en/news/286727771.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Wealthfront Advisers LLC Takes $1.74 Million Position in Insmed, Inc. $INSM](https://longbridge.com/en/news/284995222.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)